Merck Manual

Please confirm that you are a health care professional

Loading

Trachoma

(Egyptian Ophthalmia; Granular Conjunctivitis)

By

Melvin I. Roat

, MD, FACS, Sidney Kimmel Medical College at Thomas Jefferson University

Last full review/revision Oct 2019| Content last modified Oct 2019
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Topic Resources

Trachoma is a chronic conjunctivitis caused by Chlamydia trachomatis and is characterized by progressive exacerbations and remissions. It is the leading cause of preventable blindness worldwide. Initial symptoms are conjunctival hyperemia, eyelid edema, photophobia, and lacrimation. Later, corneal neovascularization and scarring of the conjunctiva, cornea, and eyelids occur. Diagnosis is usually clinical. Treatment is with topical or systemic antibiotics.

Trachoma is endemic in poverty-stricken parts of North Africa, the Middle East, the Indian subcontinent, Australia, and Southeast Asia. The causative organism is Chlamydia trachomatis (serotypes A, B, Ba, and C). In the US, trachoma is rare, occurring occasionally among Native Americans and immigrants. The disease occurs mainly in children, particularly those between the ages of 3 and 6. Older children and adults are much less susceptible because of increased immunity and better personal hygiene. Trachoma is highly contagious in its early stages and is transmitted by eye-to-eye contact, hand-to-eye contact, eye-seeking flies, or the sharing of contaminated articles (eg, towels, handkerchiefs, eye makeup).

Symptoms and Signs

Trachoma usually affects both eyes. Five stages are described in the World Health Organization grading system.

  • Trachomatous inflammation-follicular (TF): Characterized by five or more follicles in the upper tarsal conjunctiva

  • Trachomatous inflammation-intense (TI): Characterized by pronounced inflammatory thickening of the tarsal conjunctiva that obscures more than half of the normal deep tarsal vessels

  • Trachomatous scarring (TS): Characterized by scarring in the tarsal conjunctiva

  • Trachomatous trichiasis (TT): Characterized by at least one eyelash rubbing the eyeball

  • Corneal opacity (CO): Characterized by easily visible corneal opacity over the pupil

Rarely, corneal neovascularization regresses completely without treatment, and corneal transparency is restored. With treatment and healing, the conjunctiva becomes smooth and grayish white. In a population survey in the Nile Delta of Egypt, 6.5% of adults had trachoma and, of those, 13% had visual impairment and 8% were blind.

Diagnosis

  • Clinical findings (eg, tarsal lymphoid follicles, linear conjunctival scars, corneal pannus)

Diagnosis of trachoma is usually clinical because testing is rarely available in endemic areas. Lymphoid follicles on the tarsal plate or along the corneal limbus, linear conjunctival scarring, and corneal pannus are considered diagnostic in the appropriate clinical setting.

If the diagnosis is uncertain, C. trachomatis can be isolated in culture or identified by nucleic acid amplification tests (NAAT) and immunofluorescence techniques. In the early stage, minute basophilic cytoplasmic inclusion bodies within conjunctival epithelial cells in Giemsa-stained conjunctival scrapings differentiate trachoma from nonchlamydial conjunctivitis. Inclusion bodies are also found in adult inclusion conjunctivitis, but the setting and developing clinical picture distinguish it from trachoma. Palpebral vernal conjunctivitis appears similar to trachoma in its follicular hypertrophic stage, but symptoms are different, milky flat-topped papillae are present, and eosinophils (not basophilic inclusion bodies) are found in the scrapings.

Treatment

  • Antibiotics, topical or sometimes systemic

  • Surgery for eyelid deformities and/or corneal opacity

  • SAFE (Surgery, Antibiotics, Facial cleanliness, Environmental improvement) program in endemic areas

The World Health Organization (WHO) recommends that individual or sporadic cases of trachomatous inflammation-follicular (TF) be treated topically. The WHO also recommends topical treatment for trachomatous inflammation-intense (TI), but that systemic treatment should be considered. Trachomatous scarring (TS) alone does not require treatment until it progresses to cause trachomatous trichiasis (TT).

For topical treatment, tetracycline 1% ointment to both eyes twice a day for 6 weeks can be used. For systemic treatment, a single oral dose of azithromycin 20 mg/kg (maximum 1 g) is 78 to 95% effective. As an additional benefit, the use of oral azithromycin has been associated with a significant reduction in overall childhood mortality. Alternatives include doxycycline 100 mg twice a day or tetracycline 250 mg 4 times a day for 4 weeks.

The WHO recommends eyelid surgery for trachomatous trichiasis (TT). If corneal opacity (CO) has advanced into the central cornea, it is considered the stage of untreatable irreversible blindness. In resource-rich nations a corneal transplant could restore vision. The procedure is complex, and the frequent and intense aftercare to prevent rejection and infection makes corneal transplant impractical for many patients in most resource-poor nations.

Trachoma control in endemic areas

The WHO has endorsed a 4 step program for control of trachoma in endemic areas. This program is known as SAFE:

  • Surgery to correct eyelid deformities (eg, entropion and trichiasis) that place patients at risk of blindness

  • Antibiotics to treat individual patients and mass drug administration to reduce the disease burden in the community

  • Facial cleanliness to reduce transmission from infected individuals

  • Environmental improvement (eg, access to potable water and improved sanitation) to reduce transmission of disease and reinfection of patients

In hyperendemic areas, mass administration to the entire community older than 6 months of a single oral dose of azithromycin 20 mg/kg (maximum 1 g) or tetracycline or erythromycin ophthalmic ointment applied bid for 5 consecutive days each month for 6 months has been effective as treatment and prophylaxis. Endemic trachoma has been dramatically reduced by using community-wide oral azithromycin in a single dose or in repeated doses. However, reinfection due to re-exposure is common among endemic areas.

Key Points

  • Trachoma is a chronic, exacerbating, and remitting chlamydial conjunctivitis that is common among children ages 3 through 6 in certain poverty-stricken areas worldwide.

  • Manifestations develop in stages and include conjunctivitis, formation of tarsal follicles, thickening and scarring of tarsal conjunctiva, trichiasis, and corneal neovascularization and scarring.

  • About 5% of patients develop decreased vision or blindness; trachoma is the leading cause of blindness worldwide.

  • Diagnosis is usually clinical, but standard methods to detect chlamydia can be done when available.

  • Treatment is with topical or systemic antibiotics

  • For endemic areas, the World Health Organization also advocates corrective surgery, mass administration of antibiotics, emphasizing facial cleanliness, and environmental interventions to reduce transmission.

Drugs Mentioned In This Article

Drug Name Select Trade
ERY-TAB, ERYTHROCIN
ACHROMYCIN V
ZITHROMAX
PERIOSTAT, VIBRAMYCIN
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
Glaucoma
Video
Glaucoma
Inside the eye are two fluid-filled chambers. Intraocular fluid, or eye fluid, is responsible...

SOCIAL MEDIA

TOP